| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 7, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 230,000 | $224.72 | $51,685,007.87 | - | +14.9% | +42.2% | |
| Jun 7, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 10,000 | $18.74 | $187,351.00 | -11.3% | -3.7% | +112.1% | |
| Jun 7, 2021 | PCRX Pacira Biosciences, Inc. | Reinhardt Max79 | President, Rest Of World | Sell | 3,500 | $60.69 | $212,406.21 | -13.1% | -8.5% | +1.1% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 1,047 | $61.04 | $63,905.74 | -7.9% | -2.8% | +5.5% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | Laranjeira Charles Anthony61 | Chief Technical Officer | Sell | 2,117 | $61.04 | $129,215.33 | -10.2% | -2.8% | +5.5% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | Reinhart Charles A. III64 | Chief Financial Officer | Sell | 2,648 | $61.04 | $161,625.98 | -9.6% | -2.8% | +5.5% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | Winston Roy68 | Chief Clinical Officer | Sell | 2,276 | $61.04 | $138,920.21 | -8.7% | -2.8% | +5.5% | |
| Jun 4, 2021 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 7,435 | $24.60 | $182,901.00 | -7.8% | +10.2% | +192.4% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 3,930 | $61.04 | $239,875.41 | -15.8% | -2.8% | +5.5% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 14,905 | $61.04 | $909,756.49 | -19.6% | -2.8% | +5.5% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | McLoughlin Dennis64 | Chief Customer Officer | Sell | 1,895 | $61.04 | $115,665.12 | -6.4% | -2.8% | +5.5% | |
| Jun 4, 2021 | PCRX Pacira Biosciences, Inc. | Hastings Paul J75 | Director | Sell | 630 | $62.19 | $39,179.70 | -10.3% | -2.8% | +5.5% | |
| Jun 4, 2021 | AMRN Amarin Corp Plc\uk | Stack David M67 | Director | Buy | 15,000 | $4.56 | $68,465.00 | +27.3% | +21.3% | -62.2% | |
| Jun 3, 2021 | ETON Eton Pharmaceuticals, Inc. | Brynjelsen Sean | President &CEO | Buy | 5,000 | $5.96 | $29,800.00 | +0.5% | -16.3% | -53.3% | |
| Jun 3, 2021 | TLRY Tilray Brands, Inc. | Meiers James R. | Head Of Canada | Sell | 23,826 | $19.64 | $467,942.64 | -100% | -31.2% | -78.7% | |
| Jun 3, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 10,000 | $18.65 | $186,527.00 | -12.0% | +5.8% | +102.4% | |
| Jun 3, 2021 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 56,500 | $0.46 | $26,023.95 | - | - | - | |
| Jun 2, 2021 | BHC Bausch Health Companies Inc. | Ackermann Christina | EVP And General Counsel | Sell | 121,198 | $31.83 | $3,857,732.34 | -42.1% | -8.7% | -69.8% | |
| Jun 2, 2021 | PCRX Pacira Biosciences, Inc. | Manning Donald C. | Chief Medical Officer | Sell | 2,380 | $62.12 | $147,852.74 | -8.4% | -4.3% | +5.3% | |
| Jun 2, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 4,300 | $35.18 | $151,274.00 | -0.5% | -0.2% | -12.7% | |
| Jun 2, 2021 | COLL Collegium Pharmaceutical, Inc | Ciaffoni Joseph | President And CEO | Sell | 22,066 | $23.09 | $509,601.66 | -2.6% | -9.9% | -31.2% | |
| Jun 1, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Koo Richard | Director | Sell | 25,827 | $19.28 | $498,009.13 | -9.3% | +1.6% | +97.4% | |
| Jun 1, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 20,116 | $35.96 | $723,434.21 | -0.4% | -0.7% | -11.4% | |
| May 28, 2021 | TCNNF Trulieve Cannabis Corp. | D'amico Alex | Chief Financial Officer | Buy | 660 | $38.00 | $25,077.36 | +44.0% | - | - | |
| May 28, 2021 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Chief Medical Officer | Sell | 163,573 | $15.01 | $2,455,431.28 | -85.0% | -2.7% | -38.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.